应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
07666 剂泰科技-P
已收盘 07-30 16:08:20
9.650
-0.550
-5.39%
最高
10.580
最低
9.460
成交量
101.21万
今开
10.200
昨收
10.200
日振幅
10.98%
总市值
114.16亿
流通市值
104.51亿
总股本
11.83亿
成交额
999.36万
换手率
0.09%
流通股本
10.83亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
港股异动 | 剂泰科技-P(07666.HK)收涨逾14% 与Deerfield取得战略联盟成果 将聚焦“平台+管线”IP全球化合作
智通财经 · 07-23
港股异动 | 剂泰科技-P(07666.HK)收涨逾14% 与Deerfield取得战略联盟成果 将聚焦“平台+管线”IP全球化合作
港股异动 | 剂泰科技-P(07666.HK)早盘涨超11% MTS-128从PCC到完成BD仅耗时半年
智通财经 · 07-23
港股异动 | 剂泰科技-P(07666.HK)早盘涨超11% MTS-128从PCC到完成BD仅耗时半年
港股异动 | 剂泰科技-P(07666)盘中涨近11% MTS-128全球授权协议已达成 “平台+产品”打开长期成长逻辑
智通财经 · 07-21
港股异动 | 剂泰科技-P(07666)盘中涨近11% MTS-128全球授权协议已达成 “平台+产品”打开长期成长逻辑
【券商聚焦】申万宏源首予剂泰科技-P (07666)“买入”评级 指AI平台加速研发
金吾财讯 · 07-17
【券商聚焦】申万宏源首予剂泰科技-P (07666)“买入”评级 指AI平台加速研发
港股概念追踪 | 合作密集落地+巨头扎堆进场 AI制药商业化驶入快车道(附概念股)
智通财经 · 07-16
港股概念追踪 | 合作密集落地+巨头扎堆进场 AI制药商业化驶入快车道(附概念股)
港股异动 | 剂泰科技-P(07666)涨超5% MTS-128实现对外授权 公司商业模式得到市场验证
智通财经 · 07-15
港股异动 | 剂泰科技-P(07666)涨超5% MTS-128实现对外授权 公司商业模式得到市场验证
【券商聚焦】中信建投首予剂泰科技(07666)买入评级 指AI平台价值加速兑现
金吾财讯 · 07-14
【券商聚焦】中信建投首予剂泰科技(07666)买入评级 指AI平台价值加速兑现
【券商聚焦】国泰海通予剂泰科技(07666)“增持”评级 指双轮驱动模式获验证
金吾财讯 · 07-07
【券商聚焦】国泰海通予剂泰科技(07666)“增持”评级 指双轮驱动模式获验证
剂泰科技-P更新2026年6月股份变动月报，H股新增发行30,184,000股
公告速递 · 07-06
剂泰科技-P更新2026年6月股份变动月报，H股新增发行30,184,000股
剂泰科技-P早盘涨逾6% 达成16亿美元临床前TCE授权合作
新浪港股 · 07-03
剂泰科技-P早盘涨逾6% 达成16亿美元临床前TCE授权合作
港股异动 | 剂泰科技-P(07666.HK)涨超6% 达成16亿美元临床前TCE授权合作 创中国单笔记录
智通财经 · 07-03
港股异动 | 剂泰科技-P(07666.HK)涨超6% 达成16亿美元临床前TCE授权合作 创中国单笔记录
AI制药的转折点，可能就藏在这笔交易里
格隆汇 · 07-02
AI制药的转折点，可能就藏在这笔交易里
55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元
智通财经 · 07-01
55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元
剂泰科技与Deerfield达成授权合作 潜在交易总额超16亿美元
财中社 · 06-30
剂泰科技与Deerfield达成授权合作 潜在交易总额超16亿美元
中国临床前TCE单笔海外授权新纪录！剂泰科技(07666.HK)与Deerfield首个战略联盟里程碑落地
智通财经 · 06-30
中国临床前TCE单笔海外授权新纪录！剂泰科技(07666.HK)与Deerfield首个战略联盟里程碑落地
剂泰科技-P宣布与Deerfield达成临床前TCE许可合作，总价值高达16亿美元
美股速递 · 06-30
剂泰科技-P宣布与Deerfield达成临床前TCE许可合作，总价值高达16亿美元
港股异动 | 剂泰科技-P(07666.HK)涨超10% AI制药行业步入价值验证期 公司自研AI纳米递送平台
智通财经 · 06-29
港股异动 | 剂泰科技-P(07666.HK)涨超10% AI制药行业步入价值验证期 公司自研AI纳米递送平台
港股异动 | 剂泰科技-P(07666)最高涨近7% 近日正式发布AiProtein平台及抗体设计智能体AARON
智通财经 · 06-12
港股异动 | 剂泰科技-P(07666)最高涨近7% 近日正式发布AiProtein平台及抗体设计智能体AARON
异动解读｜剂泰科技-P盘中下跌5.26%，超额配发股份上市流通次日抛压持续释放
行情直击 · 06-11
异动解读｜剂泰科技-P盘中下跌5.26%，超额配发股份上市流通次日抛压持续释放
剂泰科技-P：6月10日发行30,184,000股 普通股，占已发行股本约2.87%
公告速递 · 06-10
剂泰科技-P：6月10日发行30,184,000股 普通股，占已发行股本约2.87%
加载更多
公司概况
公司名称：
剂泰科技-P
所属市场：
SEHK
上市日期：
--
主营业务：
剂泰科技（北京）股份有限公司是一家主要从事人工智能（AI）纳米材料创新的中国公司。NanoForge是该公司的人工智能驱动纳米科技创新体系的基础，涵盖脂质库、人工智能基础模型、METiS AI智能体、量子化学与分子动力学模拟及人工智能驱动的筛选平台。该公司开发了三大专业的解决方案，包括AiTEM、AiLNP及AiRNA平台，用以模拟、预测及阐释纳米级别的相互作用关系，从而实现对先进纳米材料及其相关有效载荷的合理设计、优化及验证。
发行价格：
--
{"stockData":{"symbol":"07666","market":"HK","secType":"STK","nameCN":"剂泰科技-P","latestPrice":9.65,"timestamp":1785398900762,"preClose":10.2,"halted":0,"volume":1012070,"delay":0,"changeRate":-0.05392156862745088,"floatShares":1083000000,"shares":1183000000,"eps":-5.409349491680722,"marketStatus":"已收盘","change":-0.55,"latestTime":"07-30 16:08:20","open":10.2,"high":10.58,"low":9.46,"amount":9993606,"amplitude":0.109804,"askPrice":9.79,"askSize":19500,"bidPrice":9.62,"bidSize":3500,"shortable":0,"etf":0,"ttmEps":-0.4262180662875073,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785461400000},"marketStatusCode":5,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":10.2,"openAndCloseTimeList":[[1785375000000,1785384000000],[1785387600000,1785398400000]],"volumeRatio":0.295289,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/07666","defaultTab":"news","newsList":[{"id":"2653717241","title":"港股异动 | 剂泰科技-P(07666.HK)收涨逾14% 与Deerfield取得战略联盟成果 将聚焦“平台+管线”IP全球化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2653717241","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653717241?lang=zh_cn&edition=full","pubTime":"2026-07-23 16:11","pubTimestamp":1784794291,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07666","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653718832","title":"港股异动 | 剂泰科技-P(07666.HK)早盘涨超11% MTS-128从PCC到完成BD仅耗时半年","url":"https://stock-news.laohu8.com/highlight/detail?id=2653718832","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653718832?lang=zh_cn&edition=full","pubTime":"2026-07-23 10:28","pubTimestamp":1784773728,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07666","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653322647","title":"港股异动 | 剂泰科技-P(07666)盘中涨近11% MTS-128全球授权协议已达成 “平台+产品”打开长期成长逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2653322647","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653322647?lang=zh_cn&edition=full","pubTime":"2026-07-21 13:37","pubTimestamp":1784612268,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，剂泰科技-P盘中涨近11%。消息面上，今年6月底，剂泰科技宣布与Deerfield Management 旗下Boulevard 公司达成MTS-128全球独家授权合作，公司获得2000万美元首付款，最高16亿美元里程碑付款及潜在销售分成，是目前国内临床前阶段TCE 项目最大规模的授权交易。申万宏源指出，公司依托AI平台建立多元化管线矩阵，“平台+产品”双轮驱动打开长期成长逻辑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","VXUS","BK1161","07666","KCAI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652051714","title":"【券商聚焦】申万宏源首予剂泰科技-P (07666)“买入”评级 指AI平台加速研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2652051714","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652051714?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:21","pubTimestamp":1784276472,"startTime":"0","endTime":"0","summary":"平台合作提供LNP制剂发现等服务，产品合作则整合递送系统与自有有效载荷，灵活选择自主开发或对外授权，两种模式间形成显著的飞轮协同效应。预计归属普通股东净利润于2027E转正。首次覆盖，给予“买入”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986184","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHAT","QTOC","AGIX","VTHR","AIPO","07666","KCE","ARTY","000166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651491270","title":"港股概念追踪 | 合作密集落地+巨头扎堆进场 AI制药商业化驶入快车道(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651491270","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651491270?lang=zh_cn&edition=full","pubTime":"2026-07-16 07:08","pubTimestamp":1784156921,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，AI制药商业化落地提速。英硅智能日前发布公告，旗下首款由自有生成式AI平台驱动的候选药物启动三期临床试验。过去几年，AI制药市场持续升温。英硅智能在2026年上半年迎来商业化合作的密集落地。6月10日，字节跳动AI制药业务启动拆分与独立融资的消息，在科技圈与医药圈均引发广泛关注。剂泰科技拥有中国首个完成III期临床的AI赋能制剂新药MTS-004。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","ARTY","BK1161","VXUS","BK1141","03696","BK1574","AGIX","07666","KCAI","BK4588","01477","CHAT","QTOC","VTHR","BK4585","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651332584","title":"港股异动 | 剂泰科技-P(07666)涨超5% MTS-128实现对外授权 公司商业模式得到市场验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2651332584","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651332584?lang=zh_cn&edition=full","pubTime":"2026-07-15 10:20","pubTimestamp":1784082047,"startTime":"0","endTime":"0","summary":"消息面上，剂泰科技此前宣布与Deerfield Management 旗下Boulevard 公司达成MTS-128全球独家授权合作，公司获得2000 万美元首付款，最高16亿美元里程碑付款及潜在销售分成，是目前国内临床前阶段TCE 项目最大规模的授权交易。据悉，公司作为国内领先AI纳米递送公司，平台合作+产品合作，商业模式成功得到市场验证。中信建投证券研报指出，剂泰医药AiProtein 平台能力陆续得到验证，MTS-128 全球授权标志公司从平台能力建设迈向商业化兑现的重要里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1161","BK4588","07666","VXUS","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651122399","title":"【券商聚焦】中信建投首予剂泰科技(07666)买入评级 指AI平台价值加速兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2651122399","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651122399?lang=zh_cn&edition=full","pubTime":"2026-07-14 14:02","pubTimestamp":1784008954,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指，剂泰科技-P 旗下MTS-128项目实现全球授权，标志着公司AI蛋白平台价值加速兑现。研报指出，MTS-128是由AiProtein平台驱动设计的三特异性TCE分子，在临床前阶段已展现best-in-class治疗潜力与良好安全窗口。该机构首次覆盖，给予公司“买入”评级。主要风险包括行业政策变动、研发及审批不及预期、销售不及预期以及AI技术迭代风险等。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985809","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIPO","07666","KCE","CHAT","AGIX","ARTY","VTHR","QTOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649160480","title":"【券商聚焦】国泰海通予剂泰科技(07666)“增持”评级 指双轮驱动模式获验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2649160480","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649160480?lang=zh_cn&edition=full","pubTime":"2026-07-07 14:17","pubTimestamp":1783405072,"startTime":"0","endTime":"0","summary":"该项交易创下中国制药企业临床前TCE项目单笔海外授权交易金额新纪录，潜在交易总额超16亿美元，公司将获得2千万美元首付款。此举被视为中国AI药物递送创新国际化的重要里程碑。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985272","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07666","02611","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184448624","title":"剂泰科技-P更新2026年6月股份变动月报，H股新增发行30,184,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1184448624","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184448624?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:48","pubTimestamp":1783327705,"startTime":"0","endTime":"0","summary":"剂泰科技-P于2026年7月6日公布截至2026年6月30日的股份变动月报。报告期内，公司股份总结构有所变动，主要因全面行使超额配股权所致。经公告披露，境内未上市股份（普通股）维持99,587,739股不变；H股（普通股）则从上月的1,052,926,111股增至1,083,110,111股，增加30,184,000股。这部分增发股份的面值均为人民币0.1元，总计新增注册资本人民币3,018,400元，相关发行价格为每股港币10.5元。本月末，公司法定/注册股本总额为人民币118,269,785元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07666"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648630195","title":"剂泰科技-P早盘涨逾6% 达成16亿美元临床前TCE授权合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2648630195","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648630195?lang=zh_cn&edition=full","pubTime":"2026-07-03 11:16","pubTimestamp":1783048560,"startTime":"0","endTime":"0","summary":" 剂泰科技-P盘中涨超6%，截至发稿，股价上涨5.85%，现报14.29港元，成交额586.49万港元。剂泰科技与Deerfield旗下美国生物科技公司Boulevard Bio达成全球独家许可协议。为此，剂泰科技将斩获2000万美元首付款，并有资格获得最高达到16亿美元的开发、注册及商业化里程碑付款，外加基于产品销售额的分级销售提成。 据公开披露信息，此次交易创下中国制药企业临床前TCE项目单笔海外授权交易金额新纪录，也是中国AI药物递送创新国际化的重要里程碑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-03/doc-inifnxpe3689297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","07666"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648637462","title":"港股异动 | 剂泰科技-P(07666.HK)涨超6% 达成16亿美元临床前TCE授权合作 创中国单笔记录","url":"https://stock-news.laohu8.com/highlight/detail?id=2648637462","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648637462?lang=zh_cn&edition=full","pubTime":"2026-07-03 10:17","pubTimestamp":1783045077,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07666","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648520162","title":"AI制药的转折点，可能就藏在这笔交易里","url":"https://stock-news.laohu8.com/highlight/detail?id=2648520162","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648520162?lang=zh_cn&edition=full","pubTime":"2026-07-02 09:04","pubTimestamp":1782954267,"startTime":"0","endTime":"0","summary":"一个平台被市场重新定价，很多时候就是这样悄无声息地发生。表面看只是一笔交易公告，但底下其实已经完成了一次价值跃迁。","market":"sg","thumbnail":"https://img7.gelonghui.com/column/3.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/3.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5417215","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1574","BK1191","ARTY","AIPO","01477","BK1161","CHAT","AGIX","07666"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647453054?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02335","02670","01081","07666","01609","07630","00412","09630","06636","02526","06872","01133","00100","01672","02672","01956","02272","01286","01021","01651","02696","00340","03277","00068","00600","07688","03887","06675","02553","02726","06656","09637","00376","01879","03388","01866","06938","02729","00863","02632","02723","03625","BK4588","BK4585","01511","01392","03355","03310","06106","01191","01440","02616","06658","03661","01779","02142","01236"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2647582925","title":"剂泰科技与Deerfield达成授权合作 潜在交易总额超16亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647582925","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647582925?lang=zh_cn&edition=full","pubTime":"2026-06-30 13:24","pubTimestamp":1782797040,"startTime":"0","endTime":"0","summary":"6月30日，剂泰科技-P（07666）发布公告，宣布与Deerfield旗下的BoulevardBio达成一项高达16亿美元的临床前TCE授权合作。根据该合作协议，公司将获得2000万美元的首付款，并有资格获得最高达16亿美元的开发、注册及商业化里程碑付款，外加基于产品销售额的分级销售提成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606303788169071.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606303788169071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["07666","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647377584","title":"中国临床前TCE单笔海外授权新纪录！剂泰科技(07666.HK)与Deerfield首个战略联盟里程碑落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2647377584","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647377584?lang=zh_cn&edition=full","pubTime":"2026-06-30 12:25","pubTimestamp":1782793507,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07666","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171777854","title":"剂泰科技-P宣布与Deerfield达成临床前TCE许可合作，总价值高达16亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171777854","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171777854?lang=zh_cn&edition=full","pubTime":"2026-06-30 12:07","pubTimestamp":1782792479,"startTime":"0","endTime":"0","summary":"剂泰科技-P宣布，已与Deerfield达成一项临床前TCE（T细胞衔接器）许可合作协议。根据协议条款，此项合作的总潜在价值最高可达16亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07666"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647347726","title":"港股异动 | 剂泰科技-P(07666.HK)涨超10% AI制药行业步入价值验证期 公司自研AI纳米递送平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2647347726","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647347726?lang=zh_cn&edition=full","pubTime":"2026-06-29 11:13","pubTimestamp":1782702839,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1191","07666","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642325034","title":"港股异动 | 剂泰科技-P(07666)最高涨近7% 近日正式发布AiProtein平台及抗体设计智能体AARON","url":"https://stock-news.laohu8.com/highlight/detail?id=2642325034","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642325034?lang=zh_cn&edition=full","pubTime":"2026-06-12 14:55","pubTimestamp":1781247352,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，剂泰科技-P最高涨近7%，截至发稿，涨4.36%，报13.4港元，成交额2171.54万港元。消息面上，近日，据剂泰科技官微消息，公司正式发布AiProtein平台以及抗体设计智能体AARON。AiProtein采用剂泰科技自研“干实验+湿实验+智能体”创新范式，是聚焦蛋白和抗体等大分子的设计平台。作为剂泰科技AI纳米递送平台NanoForge驱动下的第四大核心解决方案，AiProtein与AiLNP、AiRNA和AiTEM共同完成了从蛋白设计、mRNA序列设计和LNP设计的剂泰科技“火箭+卫星”端到端研发闭环。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1161","BK4588","VXUS","07666"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103193776","title":"异动解读｜剂泰科技-P盘中下跌5.26%，超额配发股份上市流通次日抛压持续释放","url":"https://stock-news.laohu8.com/highlight/detail?id=1103193776","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103193776?lang=zh_cn&edition=full","pubTime":"2026-06-11 10:47","pubTimestamp":1781146078,"startTime":"0","endTime":"0","summary":"6月11日，剂泰科技-P盘中下跌5.26%，报11.53港元，成交额1891.85万港元。该股自5月13日上市首日大涨173%后持续回调，较首日高点回撤显著。消息面上，公司超额配股权已悉数行使，涉及3018.4万股H股按发售价10.50港元发行，该批股份于6月10日正式上市交易，新增流通股供给加大市场抛压。同时，稳定价格期间已于6月7日结束，此前支撑股价的稳定价格机制正式退出，叠加部分国际配售股份未设禁售期，获利了结压力持续释放。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07666"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107549508","title":"剂泰科技-P：6月10日发行30,184,000股 普通股，占已发行股本约2.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107549508","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107549508?lang=zh_cn&edition=full","pubTime":"2026-06-10 18:22","pubTimestamp":1781086935,"startTime":"0","endTime":"0","summary":"剂泰科技(北京)股份有限公司（“剂泰科技-P”，股票代码：07666）6月10日发布翌日披露报表，宣布公司根据此前公告所述的超额配股权已于当日悉数行使，共发行及配发30,184,000股H股普通股。\n本次发行股份占发行前公司已发行股本约2.8667%，每股发行价格为10.5港元。上述发行完成后，公司已发行股本由1,052,926,111股增至1,083,110,111股。\n公司董事会确认，本次发行已获正式授权并遵守相关法规及上市规定。公告由董事会主席、执行董事兼首席执行官赖才达签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"剂泰科技-P：6月10日发行30,184,000股 普通股，占已发行股本约2.87%","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07666"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.metistechbio.com","stockEarnings":[{"period":"1week","weight":-0.044},{"period":"1month","weight":-0.3014},{"period":"3month","weight":-0.0286},{"period":"ytd","weight":-0.0286}],"compareEarnings":[{"period":"1week","weight":0.0368},{"period":"1month","weight":0.1208},{"period":"3month","weight":0.0012},{"period":"6month","weight":-0.0577},{"period":"1year","weight":0.0111},{"period":"ytd","weight":0.0069}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"剂泰科技（北京）股份有限公司是一家主要从事人工智能（AI）纳米材料创新的中国公司。NanoForge是该公司的人工智能驱动纳米科技创新体系的基础，涵盖脂质库、人工智能基础模型、METiS AI智能体、量子化学与分子动力学模拟及人工智能驱动的筛选平台。该公司开发了三大专业的解决方案，包括AiTEM、AiLNP及AiRNA平台，用以模拟、预测及阐释纳米级别的相互作用关系，从而实现对先进纳米材料及其相关有效载荷的合理设计、优化及验证。","exchange":"SEHK","name":"剂泰科技-P","nameEN":"METIS TECHBIO-P"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"剂泰科技-P(07666)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供剂泰科技-P(07666)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"剂泰科技-P,07666,剂泰科技-P股票,剂泰科技-P股票老虎,剂泰科技-P股票老虎国际,剂泰科技-P行情,剂泰科技-P股票行情,剂泰科技-P股价,剂泰科技-P股市,剂泰科技-P股票价格,剂泰科技-P股票交易,剂泰科技-P股票购买,剂泰科技-P股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"剂泰科技-P(07666)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供剂泰科技-P(07666)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}